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Increased liver tumor formation in neutral
sphingomyelinase-2-deficient mice
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Stefka D. Spassieva,* Haiyan Qin,* Hsuan-Pei Lin,* Ahmed Elsherbini,* Rebecca Wang,††
Xue Jiang,*,§§ Mariana Nikolova-Karakashian,* Guanghu Wang,1,* and Erhard Bieberich1,*,**
Department of Physiology,* University of Kentucky College of Medicine, Lexington, KY; Department of
Bioinformatics,† Key Laboratory of Cell Biology of Ministry of Public Health, College of Basic Medical Sciences,
China Medical University, Shenyang, People’s Republic of China; Department of Biology,§ Massachusetts Institute
of Technology, Cambridge, MA; Department of Neuroscience and Regenerative Medicine,** Medical College of
Georgia, Augusta University, Augusta, GA; Johns Hopkins University,†† Baltimore, MD; and Rehabilitation
Center,§§ ShengJing Hospital of China Medical University, Shenyang, People’s Republic of China

Abstract Sphingolipids are key signaling lipids in cancer.
Genome-wide studies have identified neutral SMase-2
(nSMase2), an enzyme generating ceramide from SM, as a
potential repressor for hepatocellular carcinoma. However,
little is known about the sphingolipids regulated by nSMase2
and their roles in liver tumor development. We discovered
growth of spontaneous liver tumors in 27.3% (9 of 33) of
aged male nSMase2-deficient (fro/fro) mice. Lipidomics
analysis showed a marked increase of SM in the tumor. Unexpectedly, tumor tissues presented with more than a 7-fold
increase of C16-ceramide, concurrent with upregulation of
ceramide synthase 5. The fro/fro liver tumor, but not adjacent tissue, exhibited substantial accumulation of lipid droplets, suggesting that nSMase2 deficiency is associated with
tumor growth and increased neutral lipid generation in the
tumor. Tumor tissue expressed significantly increased levels
of CD133 and EpCAM mRNA, two markers of liver cancer
stem-like cells (CSCs) and higher levels of phosphorylated
signal transducer and activator of transcription 3, an essential regulator of stemness. CD133(+) cells showed strong
labeling for SM and ceramide. In conclusion, these results
suggest that SMase-2 deficiency plays a role in the survival or
proliferation of CSCs, leading to spontaneous tumors, which is
associated with tumor-specific effects on lipid homeostasis.—
Zhong, L., J. N. Kong, M. B. Dinkins, S. Leanhart, Z. Zhu,
S. D. Spassieva, H. Qin, H-P. Lin, A. Elsherbini, R. Wang,
X. Jiang, M. Nikolova-Karakashian, G. Wang, and E. Bieberich.
Increased liver tumor formation in neutral sphingomyelinase2-deficient mice. J. Lipid Res. 2018. 59: 795–804.
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Sphingolipids, especially ceramide, sphingosine, and
sphingosine-1-phosphate, play essential roles in cell signaling (1–5). They are modulators of various aspects of biology and pathology, including aging and cancer. In cancer,
sphingolipids regulate tumor initiation, progression, metastasis, and drug resistance (1, 3, 5–9). Excess ceramide
leads to cancer cell death, reduced growth, and senescence, and may serve as a real-time predictive marker for
radiation treatment response (6, 7, 9, 10). On the other
hand, sphingosine-1-phosphate promotes inflammation,
metastasis, proliferation, vasculogenesis, and drug resistance (4, 5, 8, 11).
Mainly three pathways generate ceramide, namely the
de novo pathway, the salvage pathway, and the SM cycle
(12–14). Several enzymes are involved in the SM cycle,
including the SM synthases (SMSs) (SMS1 and SMS2)
that catalyze the conversion of ceramide to SM, and several
SMases that hydrolyze SM to generate ceramide (13, 15–18).
Acid SMase, encoded by SM phosphodiesterase (Smpd1), is
a lysosomal enzyme the deficiency of which is associated
with Niemann-Pick disease (19, 20). Four mammalian neutral SMases (nSMases) have been identified so far, among
which nSMase2 (encoded by Smpd3) appears to be the predominant nSMase in various tissues and associated pathophysiologies (12, 15, 21). Mice deficient in nSMase2 have
multiple developmental defects, including dwarfism and
delayed puberty, attributed to hypothalamic pituitary deficiency (16–18). nSMase2 is implicated in diverse cellular

Abbreviations: CerS, ceramide synthase; CSC, cancer stem-like cell;
dh, dihydro; HCC, hepatocellular carcinoma; IS, internal standard; LD,
lipid droplet; nSMase2, neutral SMase-2; ORO, Oil Red O; pStat3, phosphorylated signal transducer and activator of transcription 3; qPCR,
quantitative PCR; Smpd, SM phosphodiesterase; SMS, SM synthase;
Stat3, signal transducer and activator of transcription 3; tStat3, total signal transducer and activator of transcription 3.
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functions, including inflammation and pathophysiology of
pulmonary, circulatory, cardiac, and neurological systems
(15). It is also implicated in cancers, such as leukemia,
breast cancer, and liver cancer (22, 23). A recent genomewide study indicates that Smpd3 is a potential repressor of
hepatocellular carcinoma (HCC) (24).
Sphingolipids play essential roles in stem cell and cancer
stem-like cell (CSC) biology (2, 25–29). CSCs, also termed
cancer-initiating cells or tumor-initiating cells, are a subpopulation of cells in the tumor that possess stem cell characteristics (30, 31). They are derived from either reactivation of
dormant progenitor cells or dedifferentiation of somatic cells
(30–32). Mounting evidence has demonstrated that CSCs
contribute significantly to tumor initiation, metastasis, treatment resistance, and relapse in many cancer types, including
liver cancer (30, 31). Thus, identifying and targeting CSCs is
a promising new strategy for cancer therapy (33). Signal
transducer and activator of transcription 3 (Stat3) is a key
transcription factor in maintaining mouse embryonic stem
cell self-renewal and CSC stemness (34–37). Stat3 is phosphorylated and activated by Janus kinases (30). The activated
Stat3 translocates into the nucleus and binds to promoters of
stemness genes, including the liver CSC marker protein,
CD133, leading to their expression (30, 35).
We report here the potential function of sphingolipids
in liver tumor development using the nSMase2-deficient
(fragilitas ossium, fro/fro) mouse line (38, 39). This mouse
line was discovered in a random-bred stock of mice after
treatment with the chemical mutagen, tris(1-aziridinyl)
phosphine-sulphine (40), which caused a deletion in the
Smpd3 gene leading to loss of enzyme activity (38). These
mice show similar phenotypes as nSMase2 knockout mice
generated through gene-targeting approaches (16–18). In
our study, liver tumors were observed in 27.3% of aged
male fro/fro mice (9 of 33), accompanied by increased proliferation and apoptosis. Lipidomics studies demonstrate a
marked increase of C16-SM, C18-SM, C24:1-SM, C16-ceramide,
and dihydro (dh)C16-ceramide in the tumor tissue. The
number of CSCs was increased in fro/fro liver tumors, as
determined by quantitative (q)PCR and immunocytochemistry of marker genes CD133 and/or EpCAM. Interestingly, CD133(+) cells were labeled for high levels of SM
and ceramide. Furthermore, fro/fro liver tumors exhibited
a significant increase of ceramide synthase (CerS)5 expression and lipid droplet (LD) content, suggesting that the
lack of nSMase2 was associated with a compensatory
upregulation of sphingolipid and neutral lipid synthesis,
which may play a role in CSC proliferation/survival and
tumor formation in the fro/fro mouse.

MATERIALS AND METHODS
Materials
Oil Red O (ORO), propylene glycol, and fluoroshield supplemented with DAPI were from Sigma-Aldrich (St. Louis, MO).
Anti-Ki67 was from Novocastra (Buffalo Grove, IL). Lysenin and
anti-lysenin antibody were from Peptide Institute, Inc. (Osaka,
Japan). Anti-CD133 was from EMD Millipore (Billerica, MA).
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Anti-phosphorylated (p)Stat3 and anti-total (t)Stat3 were from
Cell Signaling Technology (Danvers, MA). Anti-ceramide rabbit
IgG was generated in our laboratory as described previously (41).
Fluorophore-conjugated secondary antibodies were from Jackson
ImmunoResearch Laboratories (West Grove, PA). The in situ
TUNEL fluorescence staining kit was from Roche (Indianapolis, IN).

Animals
The nSMase2-deficient (fro/fro) mouse line (C3H and C57Bl6
mixed background), carrying a deletion in the Smpd3 gene, was a
gift from Dr. Christophe Poirier, Indiana University, Indianapolis,
IN (38, 39). These mice were maintained in the Laboratory Animal
Service facility of the Medical College of Georgia at Augusta University according to the National Institutes of Health’s Guide for the Care
and Use of Laboratory Animals. All procedures were approved by the
Augusta University Institutional Animal Care and Use Committee.

Methods
Tissue collection. Tumor and adjacent normal tissues were collected immediately after surgery by either snap-freeze in 80°C
or fixation with 4% PFA. Frozen tissues were never allowed to
thaw after initial freezing until used for further experiments.
Fixed tissues were either embedded in optimal cutting temperature
medium or paraffin for sectioning. H&E staining and RNA analysis
were used for quality control of the integrity of the samples.
Histology, immunohistochemistry, and confocal laser microscopy. For
histology studies, paraffin-embedded tissues were sectioned into
10 m slices and stained by H&E in the Electron Microscopy and
Histology Core Laboratory at Augusta University (directed by Dr.
Sylvia B. Smith). For immunohistochemistry, frozen or paraffin
sections were immunolabeled with the antibodies listed and
images taken using a Zeiss LSM 510 upright or a Zeiss LSM 780
inverted confocal laser scanning microscope equipped with a two
photon argon laser at 488 nm (Cy2), 543 nm (Cy3), and 633 nm
(Cy5, Alexa Fluor 647), respectively. LSM 510 Meta 3.2 software
was used for image acquisition and processing. Samples labeled
with antibodies against lipids were only PFA-fixed and frozen for
cryosectioning. Images obtained with secondary antibodies were
only used as negative controls to correct for background intensity
of a particular laser channel. Antigen-specific immunolabeling
was quantified by counting cells that showed signals 2-fold or
more above background fluorescence. The percentage of Ki67and TUNEL-positive cells was counted at ×400 magnification in at
least five random fields where tumors existed.
ORO staining. Fixed frozen sections were washed with distilled water. Excess water was drained and depleted by rinsing
twice using propylene glycol. ORO was applied and incubated for
7 min at 60°C. Specimens were destained with 85% propylene
glycol, rinsed in distilled water, and counterstained using hematoxylin. After sufficient washing with water, specimens were
mounted with aqueous mounting media and microscopic images
taken using an epifluorescence microscope.
RNA extraction, RT-PCR, and qPCR. RNA was extracted using
the TriZol reagent (Invitrogen). First strand cDNA was generated
by the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Realtime qPCR was performed using SYBR green/Rox qPCR master
mix on the CFX96 Touch real-time system (Bio-Rad). The primers for qPCR were: mCerS5-forward, TAGAGAGCAGCTGAGAGGAAGAAGA; mCerS5-reverse, GAACCCAGAGTCTCAAGAGCCATGGC; mCD133-forward, CAGCAATCACTGAAATTTGTG;
mCD133-reverse, ACATCCTCTGAATCCATCCTG; mEpCAMforward, TATTTTGAAAAAGATGTGAAG; mEpCAM-reverse,
ATTAAGCTCTCTGTGGATCTC.
Sphingolipid measurement. Liver tissues were analyzed at the
Lipidomics Core of the Medical University of South Carolina

TABLE 1. Incidents of liver tumors in fro/fro mice
Genotype

Gender

Age
(months)

Number of Mice
with Tumor

Total Mouse
Number

Tumor
Ratio (%)

fro/+
fro/fro
fro/fro

Male
Female
Male

16–24
16–24
16–24

0
0
9

21
31
33

0
0
27.3

according to published protocols on a Thermo Fisher TSQ Quantum triple quadrupole mass spectrometer, operating in a multiple
reaction monitoring positive ionization mode (42). Briefly, similar
amounts of tissue were homogenized, protein concentration
determined, aliquots of the homogenates equivalent to 1.5 mg
protein fortified with internal standards (ISs), and lipids from the
fortified homogenates extracted twice with 2 ml ethyl acetate, isopropanol, and water (60:30:10 v/v/v) solvent. Lipid extracts were
evaporated and reconstituted in 150 l of 1 mM ammonium formate in 0.2% formic acid in methanol before being subjected to
LC-MS/MS on the HP1100/TSQ Quantum LC-MS/MS system.
The samples were gradient-eluted from the BDS Hypersil C8, 150 ×
3.2 mm, 3 m particle size column, with a 1.0 mM methanolic ammonium formate per 2 mM aqueous ammonium formate mobile

phase system. Peaks corresponding to the target analytes and ISs
were collected and processed using the Xcalibur software system.
Quantitative analysis was based on the calibration curves generated by spiking an artificial matrix with the known amounts of the
target analyte synthetic standards and an equal amount of the ISs.
The target analyte/IS peak area ratios were plotted against analyte
concentration. The target analyte/IS peak area ratios from the
samples were similarly normalized to their respective IS and compared with the calibration curves using a linear regression model.
Results were normalized to lipid phosphate.
Statistics. The statistical significance was calculated using Student’s t-test with Excel or one-way ANOVA and Tukey’s post hoc
test with GraphPad Prism. P < 0.05 was considered significant.

RESULTS
Aged fro/fro male mice show liver tumors
To determine a potential involvement of nSMase2 and
sphingolipids in hepatic cancer, we analyzed liver tissue in

Fig. 1. Gross and microscopic features of liver tumors in fro/fro mice. A: Tumors were observed in aged male fro/
fro mouse livers. One age-matched fro/+ control (left) and two tumors are shown (right). These tumors contained
heterogeneous nodules sized from 0.1 to 5 mm. The color of many nodules was pale, suggestive of focal fat accumulation. Scale bar = 2 mm. B: H&E staining showed two well-defined proliferation nodules within the tumor.
Scale bar = 200 m. C: Higher magnification of inset  in B. The tumor contains large and vacuolated hepatocytes
(left). Liver parenchyma was pushed to the side (right). Scale bar = 10 m. D, E: Profound cell hyperplasia
(arrowheads) (D) and lymphocyte infiltration (arrows) (E) in the tumor. Scale bars = 50 m.

Liver tumors in nSMase2-deficient mice
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aged fro/fro mice (38, 39). Spontaneous hepatic tumors
were observed in 9 out of 33 (27.3%) aged (18–24 months
old) male fro/fro mouse livers (38) (Table 1, Fig. 1A). The
phenomenon appeared to be age- and sex-dependent
because no tumors were detected in young (less than
10 months old) or in age-matched female (0 of 31) fro/fro
mice (Table 1). The incidence in aged-matched male controls (fro/+) was also 0% (0 of 21) (Table 1). The liver tumors contained heterogeneous proliferation nodules sized
0.1–5 mm in diameter (Fig. 1A). The color of many nodules
was pale, suggestive of focal fat accumulation (Fig. 1A).
H&E staining of the tumor sections revealed many welldefined proliferation nodules of varying sizes (T1 and T2,
Fig. 1B). Higher magnification of the inset  in nodule T1
indicated a clear boundary between the tumor tissue and
liver parenchyma (Fig. 1C). The hepatocytes within the tumor showed enlarged and vacuolated cytoplasm, suggesting
fat buildup (Fig. 1C). Pronounced cell hyperplasia (arrowheads, Fig. 1D) and penetration of lymphocytes along the
portal vein (arrow, Fig. 1E) were observed within the tumor.
Enhanced proliferation and apoptosis in fro/fro liver
tumors
Dysregulated cell proliferation and death is a hallmark
of cancer (43). We detected the rate of cell proliferation
and death in the fro/fro liver tumors. The number of Ki67positive cells was markedly increased in the tumors when
compared with normal adjacent tissues (Fig. 2A, C), indicating that cell proliferation was enhanced. On the other
hand, the number of TUNEL-positive cells was also markedly increased, indicating augmented apoptosis (Fig. 2B, C).
These results are consistent with clinical findings that,
although evasion of cell death pathways is a major attribute
of cancer, as tumor cells grow and exhaust the nutritional
supply from blood circulation, dead cells remain a common feature of many malignancies (44, 45).
Increased number of CSCs in fro/fro liver tumors
CSCs contribute to liver carcinogenesis (46–48). The fro/
fro liver tumors contained pockets of proliferating cells
(Figs. 1D, 2A), which could be due to the existence of CSCs.
To dissect the cell source of tumor formation, we tested for
the presence of CSCs in fro/fro liver tumors. RT-PCR and
qPCR results showed that the message levels of CD133 and
EpCAM, two markers of liver CSCs (30, 35), were increased
by 15- and 54-fold, respectively, in fro/fro liver tumors when
compared with adjacent normal tissues (Fig. 3A, B).
The IL6/JAK/Stat3 pathway is essential for stem cell
pluripotency and CSC stemness (34–37). Sphingolipids
have been shown to regulate multiple pluripotency pathways, including the Akt/GSK-3 and IL6/JAK/Stat3 pathways (3, 49–51). We tested to determine whether nSMase2
deficiency in fro/fro mice had an effect on these pathways.
Western blot analysis showed that the pStat3 level when
normalized to tStat3 was significantly increased in fro/fro
liver tumors as compared with adjacent normal tissue, indicating that the IL6/JAK/Stat3 pathway was activated in fro/fro
liver tumors (Fig. 3C, D). However, the Akt/GSK-3 pathway was not activated (not shown). To further elucidate that
798
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Fig. 2. Increased proliferation and cell death in fro/fro liver tumors. A: Proliferation was increased in fro/fro liver tumors as shown
by Ki67 labeling (green). Con, fro/+ liver tissue; Tumor, fro/fro tumor. Scale bar = 20 m. B: Apoptosis was augmented in fro/fro liver
tumors, as shown by TUNEL staining (red). Scale bars = 50 m. C:
Quantification of Ki67- and TUNEL-positive cells in A and B. N = 5.
*P < 0.05, **P < 0.01.

CSCs were increased in fro/fro liver tumors, we colabeled
for CD133 and pStat3. Figure 3E shows that there were
pockets of CD133(+) CSCs in fro/fro liver, which colabeled
exclusively with pStat3, indicating that the CD133(+) cells
were pluripotent (Fig. 3E). We could not detect CD133(+)
or pStat3(+) cells in control (fro/+) liver tissue (Fig. 3E).
Aberrant sphingolipid profile in fro/fro liver tumors
To understand the mechanism of liver tumor formation
related to sphingolipids, we analyzed the alteration of the
sphingolipid profile caused by nSMase2 deficiency. nSMase2
catalyzes SM hydrolysis to generate ceramide. Consistently,
fibroblasts from fro/fro mice showed accumulation of SM
(52). Lipidomics (LC-MS/MS) data indicated that the
major SM species in the liver, C16-, C22-, C24-, and C24:1-SM,
were slightly upregulated in normal adjacent fro/fro liver
tissue when compared with age-matched fro/+ controls
(Fig. 4A and not shown). Although consistent with a previous report (52), the differences were not statistically significant. In contrast, in the fro/fro tumors, the levels of C16- and
C18-SM and total SM were all significantly increased when
compared with normal adjacent liver tissues or to age-matched

Fig. 3. CSCs in fro/fro liver tumors. A, B: The levels of liver CSC markers CD133 and EpCAM were significantly increased in fro/fro liver tumors shown by RT-PCR (A) and qPCR (B). Con, fro/+ liver tissue; Tumor, fro/fro tumor. C, D: The level of pStat3 was significantly increased
in fro/fro liver tumors, as shown by Western blot (C) and densitometric quantification (D). E: CD133(+) (green) cells were positive for pStat3
(red). Scale bar = 20 m.

fro/+ controls (Fig. 4A). In particular, the level of C16-SM
was increased by more than 4-fold (Fig. 4A).
Surprisingly, total ceramide content was also significantly increased in fro/fro liver tumors when compared with
normal adjacent liver tissues or age-matched fro/+ controls
(Fig. 4B). The levels of C16 ceramide and dhC16 ceramide,
especially, were increased by more than 7-fold (Fig. 4B),

although they were not dominant ceramide species in the
liver (not shown). In addition, the levels of dhC16- and C24:1ceramide were significantly higher in normal adjacent
tissue of fro/fro liver than control fro/+ liver (Fig. 4B). The
level of C16-ceramde was increased in fro/fro non-tumor
tissue, but the difference was not statistically significant
when compared with fro/+ controls (not shown).
Liver tumors in nSMase2-deficient mice
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Fig. 4. Aberrant sphingolipid metabolism in fro/fro liver tumors. A: Lipidomics analyses showed that C16-,
C18-, and total SM were significantly increased in fro/fro liver tumors. Control animal was fro/+ liver; normal
adjacent tissue was from fro/fro animals that had tumors. N = 2. *, P < 0.05. B. Lipidomics analyses showed that
the levels of ceramide, especially C16-, C24-, C24:1-, and total ceramide were increased in fro/fro liver tumors.
N = 2. *P < 0.05. C: Coimmunolabeling of CD133 and SM. Scale bar = 20 m. D: Coimmunolabeling of CD133
and ceramide. Scale bar = 20 m.

To investigate whether accumulation of SM and ceramide
were associated with CSC formation, we colabeled liver
tissues with antibodies against CD133, ceramide, and SM
(pre-incubated by lysenin). CD133 reactivity was located in
cells that showed strong labeling of SM (Fig. 4C) and
ceramide (Fig. 4D), while cells with low SM/ceramide labeling were CD133(). There were no detectable CD133(+)
cells or accumulation of SM and ceramide in normal
adjacent liver tissues and age-matched fro/+ controls, suggesting that accumulation of these two sphingolipids is
associated with CSC proliferation or survival in liver.
Increased sphingolipid and neutral lipid synthesis in fro/
fro liver tumors
Next, we set out to delineate the potential mechanism of
increased ceramide synthesis in fro/fro liver tumors by measuring the levels of CerSs, especially of those that generate
C16-ceramide, which has been shown to exert pro-survival
functions (53) and was increased the most in fro/fro liver
800
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tumors (Fig. 4B). Two CerSs catalyze C16-ceramide generation, CerS5 and CerS6. RT-PCR and qPCR showed that
CerS5 expression was significantly increased when compared with normal adjacent tissues, while CerS6 was below
the detection limit (Fig. 5A, B and not shown). These data
suggest that CerS5 was distinctly upregulated in fro/fro liver
tumors, likely to compensate for deficiency of nSMase2.
Alterations of sphingolipid metabolism are often associated with an accumulation of neutral lipids and the formation of LDs in the liver (54). Recent research has found
that LD formation contributes to the development of
tumors and CSCs (55). To further characterize lipid alterations in the tumor, we visualized hepatic LD content using
ORO staining. Liver tissues from young fro/+ or fro/fro mice
exhibited little ORO staining (data not shown). Some LD
accumulation was observed in fro/+ liver tissues from aged
mice (Fig. 6A), consistent with a previous report that aging
increases lipogenesis in the liver (56). Notably, the fro/fro
liver tumors contained a substantially higher amount of LDs

Fig. 5. Aberrant synthesis of sphingolipid in fro/fro liver tumors. A: CerS5 was elevated in fro/fro tumors
shown by RT-PCR using two sets of samples. CerS2 did not change. Controls (Con) were from normal adjacent
tissues of fro/fro tumors (Tumor). GAPDH was used as loading control. B: CerS5 was elevated in fro/fro tumors
shown by qPCR. N = 3. *P < 0.05.

(Fig.6C) when compared with the adjacent normal tissue
(Fig. 6B) or age-matched controls (Fig. 6A). Interestingly,
the non-tumor tissue of the fro/fro mice (Fig. 6B) exhibited
less ORO staining than that of aged-matched fro/+ controls
(Fig. 6A). Figure 6D shows additional low magnification
ORO images of a fro/fro liver tumor (encircled by green
arrows), which clearly exhibit the profoundly higher ORO
staining in fro/fro liver tumor when compared with normal
adjacent tissues (upper panel and the area outside of green
arrow, Fig. 6D). Collectively, these data indicate that the
tumors observed in aged fro/fro mice are associated with
increased lipid accumulation in contrast to the trend
observed in non-tumor tissue, where nSMase2 deficiency
reduces LD biogenesis.

DISCUSSION
Liver cancer is one of the most fatal and common cancers worldwide. Although in recent years the occurrence of
many cancers has decreased, the occurrence rate of liver
cancer has steadily increased (57, 58). Liver cancers are
usually detected at a late stage and are highly resistant to
conventional chemo- and radiotherapy, leading to very
poor survival rates.
Genome-wide association studies and genetic analyses
have identified that impaired sphingolipid metabolism is
common in many cancers, including liver cancer (3, 24,
59, 60). A recent genome-wide methylation analysis and
epigenetic unmasking identified nSMase2 (encoded by
Smpd3) as a tumor suppressor for HCC (24). Overexpression of nSMase2 reduced cell proliferation by 50% in a HCC
cell line (24). Conversely, nSMase2 knockdown with small
hairpin RNA promoted cell invasion and migration in vitro
and increased tumor formation in vivo (24). However, the
sphingolipid metabolism affected by nSMase2 and how this
altered lipid metabolism regulates tumor formation are
not known.
In the current study, liver tumors were observed in over
a quarter of aged male fro/fro mice (Table 1, Fig. 1). There
is no report on tumor formation in nSMase2-deficient animals, most likely because studies on older mice have not
been performed. These tumors showed increased proliferation and apoptosis (Fig. 2), a common feature of many
malignancies (44, 45). Interestingly, the tumors had an

increased number of CSCs, which was confirmed by Western blot and immunofluorescence labeling of pStat3, a
stemness marker (Fig. 3) (34–37). These data indicate that
CSCs might be a cell source of the origin of the tumors in
fro/fro livers.
To study the potentially underlying mechanism, we investigated the sphingolipid metabolism affected by nSMase2
deficiency in the fro/fro mice. The fro/fro tumors showed a
profound increase of SM and ceramide levels (Fig. 4), indicating that nSMase2 deficiency induced a significant sphingolipid makeover specifically in tumor cells and likely CSCs.
This assumption is consistent with tumor-specific activation
of de novo ceramide and SM synthesis (61), possibly as a
compensatory response to the genetic nSMase2 deficiency.
Significantly higher levels of ceramides and SM have been
reported in breast cancer tissue than in normal tissue (61).
SMS2 overexpression promotes mouse liver steatosis, a major contributor to the development of HCC, whereas SMS2
deficiency has the opposite effect (62). Despite a certain
level of variation, mounting evidence has demonstrated
that sphingolipid metabolism, particularly elevation of SM
and ceramide, has essential functions in cancer development (29, 61–66). Importantly, the CSC labeling is concurrent with strong labeling for ceramide and SM (Fig. 4C, D),
suggesting that buildup of these two sphingolipids could be
a contributing factor for CSC proliferation or survival. This
is in line with previous findings that changes in SM and
ceramide metabolism associate with CSC maintenance and
resistance against apoptosis induction (9, 29, 64).
Expression of CerS5 was distinctly increased in the fro/fro
liver tumors (Fig. 5), likely accounting for the increase of
C16- and dhC16-ceramide levels. Previous studies have
shown that palmitate-induced elevation of C16-ceramide
promotes LD formation in liver cells (54) and inhibition of
de novo ceramide synthesis affects liver lipid metabolism
and LD formation in vivo (67), suggesting that an increase
of ceramide levels may account for the accumulation of
LDs in fro/fro tumors (Fig. 6). Aberrant lipid metabolism
and LD accumulation are associated with liver tumors (68).
While a small side population of CSCs may already show
initial alteration of sphingolipid metabolism in normal or
precancerous tissue, elevation of SM, CerS5, and ceramide
becomes more significant and profound once they grow
into a tumor. It is also possible that elevation of SM, CerS5,
Liver tumors in nSMase2-deficient mice

801

Fig. 6. Aberrant LD accumulation in fro/fro liver tumors. A–C: ORO staining of liver lipid LDs in the livers of age-matched fro/+ control
(A), non-tumor fro/fro (B), and fro/fro liver tumors (C). Scale bars = 5 m. D: Lower magnification images of ORO staining of fro/fro liver
tumors and normal adjacent tissues. The area encircled by green arrows is tumor. Scale bars = 20 m. Insets are shown in the right panels.

and C16-ceramide, accumulation of LDs, and activation of
Stat3 lead to dedifferentiation of mature hepatocytes into
formation and propagation of CSCs, which then causes tumor formation. These two distinct mechanisms are compatible with accumulation of LDs because of the Warburg
effect, a mitochondrial dysfunction preventing fatty acid
oxidation in cancer cells (69, 70). This mitochondrial
damage leads to a compensatory fermentation and the initiation of dysregulated cell growth, which results in proliferation and propagation of CSCs (69, 71). We will further
investigate the mechanistic connection between nSMase2
deficiency, LD formation, and liver tumor growth in future
studies.
Another question to be investigated is the genderspecific development of liver tumors in aged male, but not
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in female, fro/fro mice. This gender-specificity is probably
linked to the hypothalamus-pituitary-adrenal axis defect
caused by nSMase2 deficiency. There is evidence that HCC
is an androgen-sensitive tumor and that sex hormones promote tumor proliferation (72–75). The pituitary gland of
the smpd3 mutant mice showed reduced size, and the numbers of ACTH-positive, FSH- and LH-positive, and other
hormone-positive pituicytes were all significantly reduced
in the nSMase2-deficient mice (16, 17). In addition, our
studies on nSMse2 inhibition and deficiency on plaque formation in Alzheimer’s disease clearly showed effects in
male, but not in female, mice (76, 77). Hence, genderspecific hormonal effects may underlie the observation that
only aged male fro/fro mice developed liver tumors. Despite
these open questions, our study is the first showing that

nSMase2 deficiency is associated with CSC propagation/
survival and liver tumor formation, and will possibly spur
future studies to understand the function of sphingolipid
metabolism in age-related liver cancer.
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